If it can happen to them: misdiagnosis, women's health and the case for preventative wellness spaces
13 November 2026 · By Ola Kotun (@O)
Fame did not buy a faster diagnosis. What six women's public accounts reveal about being heard, and why clinically governed wellness spaces deserve a place in preventative care.

Some of the most famous, best-resourced women in the world have waited years, sometimes decades, to be believed about their own bodies. Wealth, recognition and access did not guarantee a timely answer. We cannot dismiss that as a problem at the edges of healthcare. We need to look at how the system is designed to listen.
In this piece I look at what their stories reveal, what the global numbers say when they are read carefully, and why I believe well-run wellness spaces could become useful places for women's preventative care, if they are built properly.
Fame did not buy a faster diagnosis
Six public women, six conditions, and a recurring concern: symptoms were heard, then explained away. Each has discussed her experience publicly. These are their reported accounts, not an independent review of their medical records, and the timelines are not all comparable.
Padma Lakshmi
EndometriosisIn her public account, debilitating period pain began at 13. She was diagnosed at 36, after being told she was delicate or had a low threshold for pain. She describes years of suffering being treated as something to endure. [1]
Venus Williams
Sjögren's syndromeWilliams describes exhaustion and breathlessness beginning in 2004, before her diagnosis in 2011. An earlier diagnosis of exercise-induced asthma did not explain the autoimmune condition eventually identified. [2][3]
Serena Williams
Postpartum pulmonary embolismAfter childbirth in 2017, Williams recognised symptoms because of her clot history. In her first-person account, repeated requests for a scan and blood thinners were initially not taken seriously. A clot in her lung was subsequently confirmed. [4]
Gabrielle Union
AdenomyosisUnion recalls nine- or ten-day periods in her early twenties and fertility difficulties attributed to age and career priorities. An adenomyosis diagnosis eventually gave her answers. Her first-person account places the diagnosis by 2016, during a fertility journey that also included further IVF. [5][6]
Naga Munchetty
AdenomyosisIn parliamentary evidence, Munchetty described severe symptoms from 15 and a private diagnosis in November 2022, aged 47. She recalled being told the symptoms were normal, despite heavy bleeding, vomiting and fainting. [7]
Halle Berry
Perimenopausal symptomsBerry publicly described severe pain after sex being assessed as herpes. She said tests were negative and she later connected her symptoms with perimenopausal vaginal dryness. This is her reported experience, not an independently reviewed clinical record. [8]
Three failures repeat
Normalisation. Pain and heavy bleeding were treated as part of being a woman. Munchetty told MPs that GPs had contacted her programme to say they had not heard of adenomyosis or been taught about it. This was her testimony, but the concern it raises about recognition deserves attention. [7]
Misattribution. Symptoms were pinned on another explanation: age, asthma, medication or an infection. Sometimes those explanations are reasonable possibilities. The failure is to stop investigating when the explanation no longer fits.
Life-stage blind spots. Menstruation, pregnancy recovery and perimenopause are where these accounts cluster. A life stage can be normal without every symptom within it being normal. The distinction matters.
Race can compound inequity. A 2024 CDC summary reported that Black women in the United States were about three times as likely as White women to die from a pregnancy-related cause. That is a population disparity, not an explanation of any one woman's experience. [9]
The uncomfortable question follows: if women with platforms and resources struggle to be heard, what happens to everyone else?
From personal stories to population evidence
The public accounts are signals, not samples. They tell us that resources do not remove every failure. Population studies help us ask how large the problem is, while also revealing how easy it is to compare the wrong measures.
Diagnosis is not one single measure
The 2019 study used records from 1994 to 2015. The university summary highlighted 770 categories in which women were older at first recorded hospital diagnosis, by about four years on average. That is an age comparison, not four extra years of waiting after symptoms began. [10][11]
Endometriosis: a documented interval
Endometriosis UK's 2026 report analysed 3,075 respondents diagnosed in the UK since 2015. Their average interval was nine years and four months, compared with eight years and ten months in the report published in 2024. These are survey findings, not a population census or a global average. [12]
Endometriosis: the global burden
WHO estimates about 10% of reproductive-age women worldwide have endometriosis. Access to early diagnosis and effective treatment remains limited in many settings, including low- and middle-income countries. [13]
Heart attacks: a historical warning
BHF reported this comparison for women versus men alongside a study of 564,412 patients discharged alive from 243 NHS hospitals in England and Wales. The combined percentage came from additional unpublished analysis. It is a historical warning, not a measured 2026 diagnosis rate. [15]
Autoimmune disease: different burdens
Conrad and colleagues studied 19 common autoimmune or immune-mediated disorders in records covering about 22 million UK individuals from 2000 to 2019. The percentages refer to those selected conditions and that study period, not every autoimmune disease or current prevalence. [17]
The health gap has an economic cost
WEF and McKinsey estimated a gap of 75 million healthy life-years annually, equivalent to about seven healthy days per woman. Their model suggests closing the gap could add at least US$1 trillion to annual global GDP by 2040. This is economic potential under stated assumptions, not a guaranteed return. [18]
Read together, these findings justify taking women's symptoms seriously and improving assessment. They do not show that every woman has a diagnostic delay, or that one mechanism explains every difference.
The global picture needs careful interpretation
Good decisions need the numbers read honestly, because easy versions overstate some things and hide others. These are the five rules I apply.
Treat public stories as signals, not samples
They show that the problem reaches women with resources. They do not establish how often it happens. The population studies address that question, within their own settings and definitions.
Know where a figure comes from
Danish hospital records and a UK patient survey answer different questions. WHO notes limited access to early endometriosis diagnosis in many settings. That is a reason to improve access, not a licence to call a UK interval a global minimum. [10][13]
Read different estimates as different methods
WHO's estimate is approximately 190 million women. A separate Global Burden of Disease 2021 analysis reported about 22 million prevalent endometriosis cases using a stricter diagnostic definition. The estimates are not directly comparable; the gap does not prove a precise amount of undercounting or a fall in prevalence. [13][14]
Compare like with like, without inventing a cause
Comparisons within a healthcare system can be informative. But equal formal access does not remove differences in disease onset, symptom presentation or care pathways. The Danish study's age differences cannot, on their own, establish that bias caused a four-year wait.
Label projections as projections
The US$1 trillion GDP estimate is a modelled opportunity for 2040, not a realised gain or a forecast for an individual wellness business. The report's roughly US$3 of economic output per US$1 in direct intervention costs is not a promised investment return. [18]
Read this way, the case remains serious. There is a large burden of illness, documented diagnostic difficulty and uneven access to care. That is enough to demand better listening, without claiming more than the evidence shows.
The space notices.
Clinicians diagnose.
Why wellness spaces belong in preventative care
Wellness spaces can support part of this work because they may have what a brief appointment cannot always offer: time, repeat contact and trust. That is my case for them, not a claim that a spa or retreat has been proven to shorten diagnosis times. Built with clinical governance, they could help symptoms be noticed, recorded and routed to the right professional.
Prevention deserves a wider setting. Movement, sleep, nutrition and appropriate risk-factor management have a place alongside medical care. During menopause, WHO identifies an opportunity to reassess health and lifestyle, with attention to bone and cardiovascular health and discussion of troublesome symptoms with a clinician. Menopause support should be a healthcare conversation, not merely a product category. [20]
The investment is already significant. GWI's 2025 monitor valued the global wellness economy at US$6.8 trillion in 2024 and projected about US$9.8 trillion by 2029. This is a broad, 11-sector economy that includes beauty, physical activity, tourism and real estate, not a women's-health market estimate. Its scale makes governance more important, not less. [19]
Nor should the wellness total be described as a share of healthcare spending. GWI's comparison with health expenditure uses differently defined, partly overlapping categories. A large market does not establish the effectiveness of the treatments it sells.
Repeat contact can become useful continuity. Gyms, members' clubs and retreats can create opportunities for recurring conversations. The value lies in joining up what someone reports over time and ensuring follow-up, rather than repeatedly reassuring her without a plan.

The current interest in women's health, menopause care, preventive health and longevity retreats is a chance to build this properly. Healthy ageing is not the same as buying more tests. A beautiful room only becomes a preventative health asset when someone is accountable for what happens next.
What a well-run wellness space should do
Life-stage health histories
Ask structured, respectful questions about periods, pregnancy, recovery, perimenopause and menopause, rather than only goals and preferences. Persistent pain or bleeding that disrupts daily life deserves assessment. Give women time to explain what has changed.
Baselines and tracking over time
Record symptoms and appropriate measures, such as blood pressure, with informed consent and a clear purpose. Testing should follow clinical guidance and individual risk, not a blanket panel sold to every visitor. Agree who reviews results and how changes are followed up.
Clinically governed referral
Name the accountable clinicians. Set escalation thresholds, documented referral pathways and arrangements for urgent concerns. The space can notice a pattern and support access; diagnosis and treatment belong to appropriately qualified healthcare professionals.
Advocacy, not just treatment
Help women prepare a symptom timeline, articulate their concerns and ask what else could explain them. Where a concern remains unresolved, support a clinical reassessment or an independent second opinion. Advocacy should complement care, not undermine it.
Programmes built around women's lives
Design menstrual health, fertility support, pregnancy recovery and menopause programmes with clinical leadership. Include bone and cardiovascular health where appropriate, while recognising that needs vary. Good care cannot be reduced to an age bracket or a fashionable package.
What it must not become
A wellness space that diagnoses without qualified clinicians, sells unproven tests or brushes symptoms off with a massage is part of the problem. Governance separates a responsible preventative service from another place where women are not taken seriously.
That includes privacy and consent, a proportionate approach to screening, honest communication about uncertainty, and independence from referral incentives. Tracking is only useful if results are reviewed; a referral is only useful if someone checks that care was reached.
What I take from this
I started my career as a nurse and went on to run health services. I read these accounts less as celebrity news than as a picture of how health systems listen. In several stories, the concern was not simply a missing test. It was what happened to what these women said.
Changing the test can change who is recognised. Edinburgh research explored sex-specific thresholds for troponin, a blood test used when a heart attack is suspected. Earlier work found improved detection in women. A later trial analysis also found more detection, but did not demonstrate improved one-year outcomes in women with myocardial injury. Better recognition is necessary; it is not the whole care pathway. [16]
The first conversation still matters. In the 2026 Endometriosis UK survey, 14% of respondents said suspected endometriosis was mentioned within their first two GP appointments, compared with 10% in the earlier survey. Those figures concern recognition of a possibility, not confirmed diagnosis, but they show why the opening questions deserve attention. [12]
Equal access is not automatically equal care. The Danish findings raise questions about sex differences in disease progression and diagnosis. They do not resolve the causes. A more individual approach requires better evidence and a willingness to revisit the first explanation, not a one-size-fits-all assumption. [10]
This is why I care about where women's health happens, not only how it is treated. Wellness spaces are not a substitute for medicine and should never pretend to be. They could be where a woman is asked a useful question, where her symptoms are written down and followed over time, and where an appropriately trained professional says, "this is worth looking at".
If you are a woman reading this, three things can help: keep a written symptom record, ask "what else could this be?", and seek clinical reassessment or a second opinion when concerns remain unresolved. None guarantees an answer, and the responsibility for good care does not belong to the patient alone. Being listened to earlier is a standard worth designing for.
Sources and further reading
Publication years and study periods are shown so historical evidence is not mistaken for a current rate. Public accounts are attributed to their speakers; projections remain labelled as projections. Evidence reviewed for publication on 13 November 2026.
- Padma Lakshmi's public accountEndometriosis Foundation of America · 2011
- Venus Williams on Sjögren's syndromeABC News / Good Morning America · 2011
- Venus Williams on seven years of symptomsPrevention · 2019
- How Serena Williams saved her own lifeSerena Williams, first-person essay · ELLE · 2022
- Gabrielle Union's adenomyosis accountESSENCE, reporting her BlogHer remarks · 2018
- The hard truth about my surrogacy journeyGabrielle Union, first-person account · TIME · 2021
- Women's reproductive health: oral evidenceHouse of Commons Women and Equalities Committee · 18 October 2023
- Halle Berry's account of perimenopausal symptomsThe Hollywood Reporter, original event reporting · 2024
- Working together to reduce Black maternal mortalityUS Centers for Disease Control and Prevention · 2024
- Population-wide differences in disease progressionWestergaard et al. · Nature Communications · 2019
- Across diseases, women are diagnosed laterUniversity of Copenhagen · 2019
- The State of Endometriosis Care in the UKEndometriosis UK · 2026 report; 2025 survey
- Endometriosis fact sheetWorld Health Organization · October 2025
- Global burden of endometriosis, 1990–2021Wang et al. · BMC Women's Health · 2025
- Women's initial heart-attack diagnosesBritish Heart Foundation · 2016
- Sex-specific thresholds of high-sensitivity troponinHigh-STEACS trial analysis · 2019
- Autoimmune disorders in 22 million UK individualsConrad et al. · The Lancet · 2023
- Closing the women's health gapWorld Economic Forum and McKinsey Health Institute · 2024
- Global Wellness Economy Monitor 2025Global Wellness Institute · 2025
- Menopause: care and healthy ageingWorld Health Organization · October 2024